American Society of Hematology

SHERPA: Blue

People

  1. Usmani
    Usmani
  2. Maclachlan
    Maclachlan
  3. Lesokhin
    Lesokhin
  4. Mailankody
    Mailankody
  5. Shah
    Shah
  6. Giralt
    Giralt
  7. Landau
    Landau
  8. Shah
    Shah
  9. Korde
    Korde
  10. Hultcrantz
    Hultcrantz

Groups

  1. Department of Medicine (73)
  2. Hematologic Malignancies, Division of (73)
  3. Center for Hematologic Malignancies (70)
  4. Graduate Medical Education (70)
  5. GME, Medicine (68)
  6. Myeloma (63)
  7. Survivorship Research (57)
  8. Hematologic Malignancies Research (56)
  9. Bone Marrow Transplant (55)
  10. CTCR Scholars (50)
Search Within
  1. "Saad Usmani"
Formats
  1. Meeting Abstract (101)
  2. Journal Article (22)
  3. Research Letter (2)
Groups
  1. Department of Medicine (73)
  2. Hematologic Malignancies, Division of (73)
  3. Center for Hematologic Malignancies (70)
  4. Graduate Medical Education (70)
  5. GME, Medicine (68)
  6. Myeloma (63)

More Groups

People
  1. Saad Usmani (125)
  2. Kylee Maclachlan (65)
  3. Alexander Lesokhin (55)
  4. Sham Mailankody (47)
  5. Urvi Shah (47)
  6. David Chung (45)

More People

Years
  1. 2025 (7)
  2. 2024 (48)
  3. 2023 (42)
  4. 2022 (28)
Publications
  1. Blood (110)
  2. Blood Advances (15)

Results (125)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • T-ICAHT: Grading and prognostic impact of thrombocytopenia after CAR T-cell therapy
    Journal Article

    Rejeski, K.; Sanz, J.; Fei, T.; Nair, M. S.; Hashmi, H.; Avigdor, A.; Beyar-Katz, O.; Bücklein, V. L.; Curran, K. J.; Einarsdottir, S.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma
    Journal Article

    Sidana, S.; Ahmed, N.; Akhtar, O. S.; Brazauskas, R.; Oloyede, T.; Bye, M.; Hansen, D.; Ferreri, C.; Freeman, C. L.; Afrough, A.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Outcomes of older adults and frail patients receiving idecabtagene vicleucel: A CIBMTR study
    Research Letter

    Akhtar, O. S.; Oloyede, T.; Brazauskas, R.; Afrough, A.; Hashmi, H.; Sidana, S.; Ahmed, N.; Bye, M.; Hansen, D.; Ferreri, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Journal Article

    Bhutani, M.; Robinson, M.; Foureau, D.; Atrash, S.; Paul, B.; Guo, F.; Grayson, J. M.; Ivanina-Foureau, A.; Pineda-Roman, M.; Varga, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: A secondary SWOG analysis
    Journal Article

    Banerjee, R.; Sexton, R.; Cowan, A. J.; Rosenberg, A. S.; Ailawadhi, S.; Rajkumar, S. V.; Kumar, S.; Dispenzieri, A.; Lonial, S.; Durie, B. G. M.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • A phase III randomized trial for frail newly diagnosed multiple myeloma patients comparing bortezomib-lenalidomide-dexamethasone (VRd-lite followed by len maintenance) with daratumumab-lenalidomide-dexamethasone (DRd followed by len+/- dara maintenance): SWOG S2209
    Meeting Abstract

    Ailawadhi, S.; Hoering, A.; Ye, J. C.; Lipe, B.; Chauncey, T. R.; Gowin, K.; Calverley, D.; Holstein, S. A.; Campagnaro, E. L.; Rosenthal, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save